F5, Inc. Free cash flow increased by 132.5% to $347.57M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 41.2%, from $246.09M to $347.57M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 10.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $172.86M | $189.94M | $79.80M | $121.28M | $62.08M | $145.85M | $144.53M | $130.23M | $150.05M | $174.42M | $156.27M | $212.18M | $153.11M | $240.45M | $194.71M | $246.09M | $273.68M | $191.93M | $149.49M | $347.57M |
| QoQ Change | — | +9.9% | -58.0% | +52.0% | -48.8% | +135.0% | -0.9% | -9.9% | +15.2% | +16.2% | -10.4% | +35.8% | -27.8% | +57.0% | -19.0% | +26.4% | +11.2% | -29.9% | -22.1% | +132.5% |
| YoY Change | — | — | — | — | -64.1% | -23.2% | +81.1% | +7.4% | +141.7% | +19.6% | +8.1% | +62.9% | +2.0% | +37.9% | +24.6% | +16.0% | +78.7% | -20.2% | -23.2% | +41.2% |